MED202

MED202 is an investigational RNA-based therapeutic being developed by Medley Therapeutics for the treatment of renal disease, specifically targeting fibrotic pathways. While some early pipeline documentation associated the renal program with the MED201 designation (which is primarily focused on idiopathic pulmonary fibrosis), MED202 represents the company's dedicated effort toward kidney-related fibrotic conditions. The program leverages Medley's platform for RNA-based medicines to address the underlying drivers of chronic kidney disease and renal fibrosis. As of early 2024, the program is in the discovery and preclinical stages, with the specific molecular target and mechanism of action remaining undisclosed by the developer.